The estimated Net Worth of Iain Mc Gill is at least $1.68 Milione dollars as of 17 November 2017. Mr. Gill owns over 8,000 units of Otonomy Inc stock worth over $2,185 and over the last 10 years he sold OTIC stock worth over $1,598,289. In addition, he makes $81,511 as Independent Director at Otonomy Inc.
Sign up
Mr. McGill OTIC stock SEC Form 4 insiders trading
Iain has made over 4 trades of the Otonomy Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 8,000 units of OTIC stock worth $374,640 on 17 November 2017.
The largest trade he's ever made was exercising 8,000 units of Otonomy Inc stock on 17 November 2017 worth over $374,640. On average, Iain trades about 870 units every 38 days since 2014. As of 17 November 2017 he still owns at least 28,383 units of Otonomy Inc stock.
You can see the complete history of Mr. Gill stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Iain McGill biography
Iain R. McGill serves as Independent Director of the Company. Since June 2019, Mr. McGill has served as Chief Executive Officer and as a member of the board of directors of Quell Therapeutics, a cell and gene therapy company in the immune dysregulations field. From July 2010 to June 2019, Mr. McGill served in various positions at Jazz Pharmaceuticals plc, an international biopharmaceutical company, and, prior to its acquisition by Jazz Pharmaceuticals in 2012, EUSA Pharma, a specialty pharmaceutical company, including as Senior Vice President, Europe and Rest of World from March 2015 to June 2019, as Head of EUSA Pharma and Senior Vice President, Jazz Pharmaceuticals from March 2014 to March 2015, and as Chief Commercial Officer, EUSA Pharma, from June 2012 to March 2014. From 2006 to 2009, Mr. McGill served as Vice President and Global Business Manager for Transplantation and Immunology at Wyeth, a pharmaceutical company acquired by Pfizer Inc. Mr. McGill holds a Bachelor of Science degree in Biochemistry from the University of London.
What is the salary of Iain McGill?
As the Independent Director of Otonomy Inc, the total compensation of Iain McGill at Otonomy Inc is $81,511. There are 8 executives at Otonomy Inc getting paid more, with David Weber having the highest compensation of $2,153,120.
How old is Iain McGill?
Iain McGill is 47, he's been the Independent Director of Otonomy Inc since 2016. There are 13 older and no younger executives at Otonomy Inc. The oldest executive at Otonomy Inc is James Breitmeyer, 66, who is the Independent Director.
What's Iain McGill's mailing address?
Iain's mailing address filed with the SEC is C/O OTONOMY, INC., 4796 EXECUTIVE DRIVE, SAN DIEGO, CA, 92121.
Insiders trading at Otonomy Inc
Over the last 10 years, insiders at Otonomy Inc have traded over $30,282,796 worth of Otonomy Inc stock and bought 755,065 units worth $12,114,945 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Holdings A/S Novo e Brian H Dovey. On average, Otonomy Inc executives and independent directors trade stock every 66 days with the average trade being worth of $7,317. The most recent stock trade was executed by Vickie L Capps on 28 November 2022, trading 42,242 units of OTIC stock currently worth $4,224.
What does Otonomy Inc do?
Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière's disease, hearing loss, and tinnitus.
What does Otonomy Inc's logo look like?
Complete history of Mr. Gill stock trades at Jazz Pharmaceuticals plc e Otonomy Inc
Otonomy Inc executives and stock owners
Otonomy Inc executives and other stock owners filed with the SEC include:
-
David Weber,
President, Chief Executive Officer, Director -
Dr. David Allen Weber,
Pres, CEO & Director -
Paul Cayer,
Chief Financial and Business Officer -
Robert Savel,
Chief Technical Officer -
Paul E. Cayer,
Chief Financial & Bus. Officer -
Robert Michael Savel II,
Chief Technical Officer -
Jay Lichter,
Independent Chairman of the Board -
Vickie Capps,
Independent Director -
Iain McGill,
Independent Director -
James Breitmeyer,
Independent Director -
Theodore Schroeder,
Independent Director -
Dr. Jay B. Lichter Ph.D.,
Co-Founder & Independent Chairman -
Ciara Kennedy,
Independent Director -
James Branch CPA,
VP of Fin. & Controller -
David Skarinsky,
Sr. VP of Clinical -
Breianna Bowen,
VP of HR -
Fabrice Piu Ph.D.,
Sr. VP of Preclinical Devel. -
Barbara M. Finn,
Sr. VP of Regulatory Affairs & Quality Assurance -
Dr. Alan Charles Foster Ph.D.,
Chief Scientific Officer -
Julie D. Burgess,
VP of Fin. & Admin. -
Dr. Rick Adam Friedman M.D., Ph.D.,
Co-Founder and Member of the Advisory Panel -
Dr. Allen F. Ryan Ph.D.,
Co-Founder and Member of the Advisory Panel -
Katherine Mary Bishop,
Chief Scientific Officer -
Eric J Loumeau,
GC & Chief Compliance Officer -
Carl Le Bel,
Chief Scientific Officer -
Heather Preston,
Director -
George J Morrow,
Director -
Advisors Llc Orbi Med Capit...,
-
Chau Quang Khuong,
Director -
Anthony J Yost,
Chief Commercial Officer -
Dean Hakanson,
Chief Medical Officer -
John P Mckearn,
Director -
Partners Viii, L.P.Blair Ja...,
-
Ventures Viii Lp Avalon Ven...,
-
Holdings A/S Novo,
10% owner -
Group Holdings (Sbs) Adviso...,
-
Viii Associates, L.P.Domain...,
-
Alan Charles Foster,
Chief Scientific Officer -
Brian H Dovey,
Director -
Jill Marie Broadfoot,
Director